Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

Dubai, April 3, 2026 – Novo Nordisk will present the ORION study at the upcoming Obesity Medicine Association’s annual conference in San Diego showing that Wegovy^® (semaglutide) tablets 25 mg was associated with significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison. It is important to note that the FDA recently approved orforglipron under the brand name Foundayo™ at doses ranging up to 17.2 mg. The approved 17.2 mg tablet is the equivalent to the orforglipron 36 mg capsules used in Phase 3 trials, and which served as the study comparator in ORION. Additionally, in a separate patient preference study, adults with overweight or obesity showed greater preference for an oral semaglutide–like profile than an orforglipron-like profile.^1,2 These findings suggest potential differentiation and provide valuable insights to inform clinical decision-making.